Stock KIMIABL KIMIA BIOSCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Kimia Biosciences Limited

Equities

KIMIABL

INE285U01025

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:58 2024-06-19 am EDT 		5-day change 1st Jan Change
54 INR +0.28% Intraday chart for Kimia Biosciences Limited -4.17% +46.74%
Jun. 14 Kimia Biosciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
Jun. 14 Kimia Biosciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 380.7 518.8 927.1 1,796 1,779 1,538
Enterprise Value (EV) 1 564.7 823.9 1,301 2,283 2,231 2,118
P/E ratio 9.49 x 25.6 x 70.6 x 35.2 x -48 x -16.4 x
Yield - - - - - -
Capitalization / Revenue 0.65 x 0.55 x 0.87 x 1.35 x 1.42 x 1.2 x
EV / Revenue 0.96 x 0.88 x 1.22 x 1.72 x 1.79 x 1.65 x
EV / EBITDA 12.2 x 14.4 x 26.1 x 27.4 x 380 x -70.5 x
EV / FCF -4.49 x -11.7 x -12.3 x -15.5 x 39.6 x -31.3 x
FCF Yield -22.3% -8.54% -8.12% -6.44% 2.53% -3.19%
Price to Book 27.3 x 9.51 x 6.98 x 9.74 x 11.9 x 28.1 x
Nbr of stocks (in thousands) 7,385 14,594 46,354 47,313 47,313 47,313
Reference price 2 51.55 35.55 20.00 37.95 37.60 32.50
Announcement Date 9/3/18 9/5/19 9/6/20 9/2/21 9/7/22 9/9/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 587.1 939.2 1,063 1,327 1,249 1,285
EBITDA 1 46.16 57.27 49.75 83.29 5.866 -30.03
EBIT 1 40.42 46.62 33.86 64.68 -23.1 -62.75
Operating Margin 6.88% 4.96% 3.19% 4.87% -1.85% -4.88%
Earnings before Tax (EBT) 1 40.56 38.06 12.26 55.34 -50.18 -123.9
Net income 1 40.56 38.55 13.81 51.04 -37.03 -93.52
Net margin 6.91% 4.1% 1.3% 3.85% -2.96% -7.28%
EPS 2 5.430 1.390 0.2832 1.079 -0.7827 -1.980
Free Cash Flow 1 -125.9 -70.39 -105.7 -147.1 56.38 -67.59
FCF margin -21.44% -7.49% -9.94% -11.08% 4.51% -5.26%
FCF Conversion (EBITDA) - - - - 961.16% -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 9/3/18 9/5/19 9/6/20 9/2/21 9/7/22 9/9/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 184 305 374 488 452 580
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 3.986 x 5.326 x 7.514 x 5.856 x 77.12 x -19.32 x
Free Cash Flow 1 -126 -70.4 -106 -147 56.4 -67.6
ROE (net income / shareholders' equity) 170% 47% 11.8% 32.1% -22.2% -91.9%
ROA (Net income/ Total Assets) 8.78% 4.71% 2.8% 4.2% -1.34% -3.4%
Assets 1 461.9 817.9 493 1,214 2,773 2,752
Book Value Per Share 2 1.890 3.740 2.860 3.900 3.150 1.150
Cash Flow per Share 2 0.5900 0.0600 0.0500 0.1200 0.0400 0.0400
Capex 1 20.2 25.8 90.1 136 35.8 28.1
Capex / Sales 3.45% 2.75% 8.48% 10.22% 2.87% 2.19%
Announcement Date 9/3/18 9/5/19 9/6/20 9/2/21 9/7/22 9/9/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
KIMIA BIOSCIENCES LIMITED Stock Kimia Biosciences Limited
+46.74% 30.56M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+52.93% 803B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.98% 629B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.08% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.40% 324B
ABBVIE INC. Stock AbbVie Inc.
+10.58% 303B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.42% 244B
ROCHE HOLDING AG Stock Roche Holding AG
+2.17% 226B
NOVARTIS AG Stock Novartis AG
+10.66% 215B
AMGEN INC. Stock Amgen Inc.
+6.24% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. KIMIABL Stock
  4. Financials Kimia Biosciences Limited